CO5160262A1 - Formulaciones farmaceuticas de liberacion controlada - Google Patents

Formulaciones farmaceuticas de liberacion controlada

Info

Publication number
CO5160262A1
CO5160262A1 CO99066970A CO99066970A CO5160262A1 CO 5160262 A1 CO5160262 A1 CO 5160262A1 CO 99066970 A CO99066970 A CO 99066970A CO 99066970 A CO99066970 A CO 99066970A CO 5160262 A1 CO5160262 A1 CO 5160262A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical formulations
controlled liberation
liberation
controlled
formulations
Prior art date
Application number
CO99066970A
Other languages
English (en)
Inventor
Elizabeth King
Ross James Macrae
Original Assignee
Pfizzer Res And Dev Company N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5160262(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizzer Res And Dev Company N filed Critical Pfizzer Res And Dev Company N
Publication of CO5160262A1 publication Critical patent/CO5160262A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención proporciona formulaciones farmacéuticas de liberación controlada para administración oral que contienen un inhibidor GMPc PDE-5. Las formulaciones son útiles, entre otros, en el tratamiento o prevención de la disfunción sexual.
CO99066970A 1998-10-23 1999-10-22 Formulaciones farmaceuticas de liberacion controlada CO5160262A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CO5160262A1 true CO5160262A1 (es) 2002-05-30

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99066970A CO5160262A1 (es) 1998-10-23 1999-10-22 Formulaciones farmaceuticas de liberacion controlada

Country Status (44)

Country Link
US (1) US6964780B1 (es)
EP (1) EP1123088B1 (es)
JP (1) JP2002528408A (es)
KR (1) KR20010075659A (es)
CN (1) CN1324233A (es)
AP (1) AP2001002125A0 (es)
AT (1) ATE340562T1 (es)
AU (1) AU756509B2 (es)
BG (1) BG65323B1 (es)
BR (1) BR9914718A (es)
CA (1) CA2348086C (es)
CO (1) CO5160262A1 (es)
CR (1) CR6326A (es)
CY (1) CY1106239T1 (es)
CZ (1) CZ20011427A3 (es)
DE (1) DE69933383T2 (es)
DK (1) DK1123088T3 (es)
DZ (1) DZ2923A1 (es)
EA (1) EA004068B1 (es)
EE (1) EE200100235A (es)
ES (1) ES2272082T3 (es)
GT (1) GT199900184A (es)
HK (1) HK1041818A1 (es)
HR (1) HRP20010285A2 (es)
HU (1) HUP0104318A3 (es)
ID (1) ID28232A (es)
IL (1) IL141764A (es)
IS (1) IS5865A (es)
MA (1) MA26700A1 (es)
MX (1) MXPA01004011A (es)
MY (1) MY130727A (es)
NO (1) NO20011933L (es)
NZ (1) NZ510275A (es)
OA (1) OA11664A (es)
PA (1) PA8484301A1 (es)
PE (1) PE20001286A1 (es)
PL (1) PL195789B1 (es)
PT (1) PT1123088E (es)
SK (1) SK286473B6 (es)
TR (1) TR200101103T2 (es)
TW (1) TW577756B (es)
UA (1) UA67802C2 (es)
UY (1) UY25765A1 (es)
WO (1) WO2000024383A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287161B6 (sk) * 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
PT1126826E (pt) 1998-11-02 2008-11-25 Elan Pharma Int Ltd Composição de metilfenidato de libertação modificada multiparticulada
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7501409B2 (en) * 2000-09-06 2009-03-10 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
NZ527585A (en) 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
WO2005107810A2 (en) * 2004-05-11 2005-11-17 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US20090118211A1 (en) * 2005-06-27 2009-05-07 Daniel Drai Compositions and Methods for Enhancement of Sexual Function
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
AU2007287639A1 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
WO2010067140A1 (es) * 2008-12-12 2010-06-17 Siegfried Rhein S.A. De C.V. Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
MX353623B (es) 2011-05-13 2018-01-22 Eb Ip Hybritabs B V Sistema de suministro de farmaco.
WO2013016144A1 (en) * 2011-07-22 2013-01-31 Pom Wonderful, Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
AU715867B2 (en) * 1997-01-06 2000-02-10 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US6077841A (en) * 1998-09-04 2000-06-20 Janssen Pharmaceutica, N.V. 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction

Also Published As

Publication number Publication date
HUP0104318A3 (en) 2003-12-29
CR6326A (es) 2004-02-23
NO20011933D0 (no) 2001-04-19
DE69933383T2 (de) 2007-02-01
IS5865A (is) 2001-02-27
NO20011933L (no) 2001-06-25
HUP0104318A2 (hu) 2002-03-28
US6964780B1 (en) 2005-11-15
PT1123088E (pt) 2007-01-31
BR9914718A (pt) 2001-07-10
ATE340562T1 (de) 2006-10-15
SK286473B6 (sk) 2008-11-06
CA2348086C (en) 2007-01-23
UY25765A1 (es) 2001-08-27
PE20001286A1 (es) 2000-11-22
EP1123088B1 (en) 2006-09-27
MXPA01004011A (es) 2003-03-10
CY1106239T1 (el) 2011-06-08
TR200101103T2 (tr) 2001-09-21
EE200100235A (et) 2002-08-15
EP1123088A1 (en) 2001-08-16
CN1324233A (zh) 2001-11-28
IL141764A (en) 2008-06-05
DK1123088T3 (da) 2007-01-02
SK5192001A3 (en) 2002-09-10
IL141764A0 (en) 2002-03-10
UA67802C2 (uk) 2004-07-15
JP2002528408A (ja) 2002-09-03
EA200100298A1 (ru) 2001-08-27
BG105465A (bg) 2001-12-29
DE69933383D1 (de) 2006-11-09
CA2348086A1 (en) 2000-05-04
NZ510275A (en) 2003-07-25
CZ20011427A3 (cs) 2001-10-17
MA26700A1 (fr) 2004-12-20
PL195789B1 (pl) 2007-10-31
WO2000024383A1 (en) 2000-05-04
MY130727A (en) 2007-07-31
KR20010075659A (ko) 2001-08-09
GT199900184A (es) 2001-04-14
ES2272082T3 (es) 2007-04-16
ID28232A (id) 2001-05-10
PL347476A1 (en) 2002-04-08
BG65323B1 (bg) 2008-02-29
AU756509B2 (en) 2003-01-16
AP2001002125A0 (en) 2001-04-04
HK1041818A1 (zh) 2002-07-26
AU5878799A (en) 2000-05-15
EA004068B1 (ru) 2003-12-25
DZ2923A1 (fr) 2004-03-01
TW577756B (en) 2004-03-01
OA11664A (en) 2005-01-07
PA8484301A1 (es) 2000-09-29
HRP20010285A2 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ES2183937T3 (es) Inhibidores de la adhesion celular.
CR9465A (es) Compuestos mejorados farmacocineticamente
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
AR015946A1 (es) Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis
SV1998000029A (es) Compuestos de pirazina ref. pg3186
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
GT199900053A (es) Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
GT199700009AA (es) Terapia combinada para la osteoporosis
GT200100132A (es) Derivados de pirazol
PA8465901A1 (es) Nuevos derivados de la eritromicina
GT199900183A (es) Pirazolopirimidonas inhibidoras de gmp de5 para el tratamiento de la disfunciòn sexual.
AR013479A1 (es) Metodo para aumentar el volumen oseo utilizando agonistas de prostanoide f selectivos no naturales.
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
ES2164447T3 (es) Procedimiento de inhibicion de resorcion del hueso.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.